About Event

CRISPR 2.0 is dedicated to showcasing the next generation of CRISPR tools and their innovative applications. It’s time to step away from 1.0 CRISPR technology. Rather than attending yet another CRISPR meeting that covers old ground, CRISPR 2.0 will offer you the opportunity to:

  • Discuss methods to overcome CRISPR delivery challenges and delve into the latest delivery platforms with innovative work on the developments of viral and non-viral candidates suitable for ex-vivo and in-vivo delivery with Scribe Therapeutics and AskBio
  • Explore the potential of novel prime and base editing, improving on editing accuracy. Hear directly from Andrew Anzalone, the pioneer that developed prime editing and Astrazeneca on how to improve safety
  • Accelerate the development of therapeutics utilizing CRISPR and discover the clinical applications that are being studied with insights and data from Intellia Therapeutics, and Graphite Bio
  • Investigate novel Cas variants and understand how novel Cas proteins that optimize specificity and efficacy of gene editing will be vital to bringing CRISPR successfully into the clinic with Arbor Biotech and Harvard Medical School